Key Specifications Table
Pricing & Availability
An invalid quantity was specified. The product quantity has been adjusted.
|5.09230.0001||Glass bottle||10 mg||
|Overview||A cell-permeable, non-toxic, dihydropyrimidine compound that prevents cellular glycosylation and surface expression of Notch, APP, Klotho (Effect. conc. = 10 µM in HEK293, HeLa, U2OS cultures) in a rapid and reversible manner by blocking events prior to cargo assembly at the ER exit sites (ERES) without affecting other post-ERES events targeted by BFA, GCA, Exo1, A5, Retro-2, U18666A, or Vacuolin-1 (Cat. nos. 203729, 345862, 341220, 444805, 554715, 662015, & 673000, respectively). Notch signaling is shown to be effectively inhibited by treatment with either FLI-06 or the γ-Secretase inhibitior DAPT (Cat. nos. 565770 & 565784) in both C2C12 cultures (10 µM FLI-06) in vitro and in zebrafish embryos (50 µM FLI-06) in vivo.|
|Synonyms||Cyclohexyl 2,7,7-trimethyl-4-(4-nitrophenyl)-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate, Cyclohexyl 4-(4ʹ-nitrophenyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate, FLI06|
|References||Kramer, A., et al. 2013. Nat. Chem. Biol. 9, 731.|
|Purity||≥95% by HPLC|
|Safety Information according to GHS|
|Product Usage Statements|
|Packaged under inert gas||Packaged under inert gas|
|Kramer, A., et al. 2013. Nat. Chem. Biol. 9, 731.|
Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.